By Mitul Agarwal, B.Pharm, MBA. Published October 2026.
Short answer: the drug substance is the active ingredient itself, the API, for example metformin hydrochloride powder. The drug product is the finished medicine a patient takes, for example metformin 500 mg tablets: the drug substance combined with excipients, made into a dosage form and packed. The two are often made at different sites, always under different GMP rules, and are documented in different parts of a dossier.
The definitions regulators use
- Drug substance: the active ingredient intended to produce the medicine's pharmacological effect. US regulations define it this way and exclude the intermediates used to make it. ICH uses "drug substance" and "active pharmaceutical ingredient (API)" for the same thing. In India it is often called a bulk drug.
- Drug product: the finished dosage form, such as a tablet, capsule, solution or injection, that contains the drug substance, usually with other ingredients. WHO calls it a finished pharmaceutical product (FPP); traders say FDF (finished dosage form) or "formulation"; EU law says medicinal product.
Side by side
| Drug substance (API) | Drug product (FDF) | |
|---|---|---|
| What it is | The active ingredient, usually a powder or crystalline solid (for biologics, a purified protein solution) | The finished medicine: tablets, capsules, syrups, vials, inhalers, patches |
| Made by | Chemical synthesis, fermentation, extraction or (for biologics) cell culture and purification | Formulation: blending with excipients, granulation, compression, filling, sterilisation, packing |
| Made in | API plants | Formulation plants, often owned by a different company |
| GMP standard | ICH Q7 (EU GMP Part II) | EU GMP Part I; US 21 CFR 210 and 211; WHO GMP for FPPs |
| Dossier section (CTD) | Module 3.2.S | Module 3.2.P |
| Regulatory file | US DMF (Type II), EU CEP or ASMF | The product's marketing authorisation (NDA, ANDA, MA) |
| Specification guideline | ICH Q6A (chemicals) or Q6B (biologics): identity, assay, impurities, residual solvents, particle size, polymorph | ICH Q6A or Q6B: identity, assay, dissolution, uniformity, impurities, microbial limits, sterility where relevant |
| Stability | ICH Q1A (chemicals) or Q5C (biologics) studies on the API in its container; gives a retest period | ICH Q1A or Q5C studies on the product in its final pack; gives the shelf life |
| Who buys it | Formulation manufacturers and CDMOs | Importers, distributors, hospitals, governments and pharmacies |
The supply chain in between
Drug substance and drug product are two points on one chain:
- Key starting material (KSM): the chemical building block that the registered API process starts from.
- Intermediates: compounds made along the synthesis route.
- Drug substance (API): the final active ingredient, tested and released against its specification.
- Excipients: fillers, binders, disintegrants, lubricants, coatings, solvents and preservatives.
- Drug product: the formulated, packed and released medicine.
API GMP (ICH Q7) applies from the point the starting material enters the registered process, and becomes stricter towards the final steps. A change at any step, such as a new KSM supplier or a new API site, can trigger a regulatory variation for the drug product.
Biologics: the same words, a different picture
For a monoclonal antibody or vaccine, the drug substance is the purified bulk protein produced by cell culture. The drug product is that protein formulated, filled into vials or prefilled syringes and labelled. The two steps are often at different sites, and fill-finish is one of the most outsourced parts of biologics manufacturing. Our guide to injectable and sterile CDMOs covers what to check at a fill-finish partner.
Why the difference matters to buyers
- Buying a finished product? Ask where the API comes from as well as where the product is made. The importing regulator will usually ask too. The API source is named in the dossier, and changing it needs a variation.
- Buying an API? Check its documents: a DMF, CEP or ASMF, the GMP certificate of the API site and, for export to the EU, the written confirmation from the exporting country's regulator (unless that country is on the EU's equivalence list). Our guide to CEP vs DMF vs ASMF explains which one you need.
- Registering a product? Your dossier needs both parts: 3.2.S for the drug substance (often covered by the API maker's DMF or CEP) and 3.2.P for the drug product. See CTD vs ACTD.
- Comparing two suppliers of the "same" product? Same API and same strength does not mean the same product. Excipients, process and pack all differ, which is why regulators ask for bioequivalence data for most oral generics.
How PharmaTradz can help
PharmaTradz connects buyers with manufacturers of both APIs and finished formulations. Tell us whether you need the drug substance or the drug product, the grade or strength, and the destination market, and we share each supplier's document status before you commit. Use our documentation and quality pack to collect GMP, CoPP and CoA documents, or send an RFQ. Terms like KSM, CoA and CoPP are explained in our six-language pharma glossary.
Frequently Asked Questions(FAQs)
Is a drug substance the same as an API?
Yes. "Drug substance" and "active pharmaceutical ingredient (API)" mean the same thing in ICH guidelines. In India the same material is often called a bulk drug.
What is an example of a drug substance and a drug product?
Paracetamol powder made at an API plant is the drug substance. Paracetamol 500 mg tablets, made from that powder with excipients and packed in blisters, are the drug product.
Which part of the CTD covers each?
Module 3.2.S covers the drug substance and Module 3.2.P covers the drug product. The 3.2.S part is often supported by the API maker's DMF, CEP or ASMF.
Do drug substance and drug product follow the same GMP rules?
No. API manufacture follows ICH Q7 (EU GMP Part II). Finished products follow EU GMP Part I, US 21 CFR 210 and 211, or WHO GMP for finished pharmaceutical products.
What is the drug substance for a biologic?
The purified bulk protein produced by cell culture. The drug product is that protein after formulation, filling into vials or syringes, and labelling.
